Physician profile
Robert Ford
NPI 1891972428
$2,656.98
in general payments reported to CMS, 2019-2025
24 companies · $401 in 2025
The $401 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $255 · 2021: $356 · 2022: $535 · 2023: $404 · 2024: $299 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $602.40 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $584.77 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $368.97 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $153.27 | 2019-2024 | Bexsero |
| Pfizer INC. | $119.57 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.41 | 2019-2022 | |
| Kaleo, INC. | $85.53 | 2019-2022 | |
| Sobi, INC | $84.64 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $75.64 | 2021-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $75.42 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $72.93 | 2019-2023 | Adzenys Xr-Odt |
| Seqirus USA INC | $66.85 | 2025 | Flucelvax |
| Cranial Technologies, INC | $55.84 | 2019-2025 | Doc Band |
| Noven Therapeutics, LLC | $41.53 | 2024-2025 | Xelstrym |
| Kowa Pharmaceuticals America, INC. | $31.26 | 2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.44 | 2019 | |
| Adlon Therapeutics L.P. | $23.06 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $17.40 | 2025 | Neffy |
| Advanced Respiratory, INC | $14.84 | 2019 | |
| Immedica Pharma US, INC. | $14.81 | 2023 | |
| Sanofi-Aventis U.S. LLC | $14.46 | 2025 | |
| Baxter Healthcare | $13.48 | 2025 | |
| Merck Sharp & Dohme LLC | $13.28 | 2020 | |
| Mylan Pharmaceuticals INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.